We’re lowering our price target on Bristol Myers as two key overhangs persist

0 Min Read

Shares were down around 5% on Thursday afternoon despite a beat-and-raise quarter.

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Exit mobile version